Cardiovascular effects of amezinium in humans during passive upright tilt in comparison with norfenefrine and dihydroergotamine. 1981

K Wilsmann, and G Neugebauer, and R Kessel, and E Lang

20 min after single i.v. administration of 10 mg 4-amino-6-methoxy-1-phenyl-pyridazinium methyl sulfate (ameziniummetilsulfate, LU 1631, Regulton), in the following briefly called amezinium, a new antihypotensive agent, was studied in comparison with 10 mg norfenefrine i.m. and 1 mg dihydroergotamine i.m. during orthostatic stress on a tilt table in a total group of 29 healthy volunteers with stable cardiovascular conditions. The study of each substance was preceded by a control tilting test. After amezinium a higher systolic blood pressure of 10 to 15 mmHg in comparison with the control test was maintained during 5 min upright tilt with both a smaller increase in the rise of heart rate and decrease in stroke volume. In comparison with control, pulse pressure was also clearly increased whereas cardiac output and total peripheral resistance were not significantly different. The increase in stroke volume in comparison with control was a result of the positive inotropic effect on the one hand, which could be seen in both a diminished prolongation of the preejection period and increase in the PEP/LVET ratio, and an increased venous return to the heart on the other hand. Systolic blood pressure and heart rate after norfenefrine were principally similar to those after amezinium, whereas the effect on stroke volume was of minor magnitude because of the absence of a positive inotropic action. Moreover, cardiac output decreased more with higher total peripheral resistance in comparison to control. Besides a slight reduction in heart rate, dihydroergotamine did not reveal any significant differences from control during orthostatic stress. At the dose studied, amezinium seemed to produce a better adaptation to passive upright tilt than the reference substances.

UI MeSH Term Description Entries
D008297 Male Males
D009655 Octopamine An alpha-adrenergic sympathomimetic amine, biosynthesized from tyramine in the CNS and platelets and also in invertebrate nervous systems. It is used to treat hypotension and as a cardiotonic. The natural D(-) form is more potent than the L(+) form in producing cardiovascular adrenergic responses. It is also a neurotransmitter in some invertebrates. Norsynephrine,p-Octopamine,para-Octopamine,4-Octopamine,Norsympatol,alpha-(Aminoethyl)-4-hydroxybenzenemethanol
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D011187 Posture The position or physical attitude of the body. Postures
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004087 Dihydroergotamine A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS. Agit,Angionorm,Clavigrenin,D-Tamin Retard L.U.T.,D.H.E. 45,DET MS,DHE-45,DHE-Puren,DHE-Ratiopharm,Dihydergot,Dihydroergotamin AL,Dihydroergotamine Mesylate,Dihydroergotamine Methanesulfonate,Dihydroergotamine-Sandoz,Dihytamin,Erganton,Ergomimet,Ergont,Ergotam Von Ct,Ikaran,Migranal,Orstanorm,Seglor,Tamik,Verladyn,D Tamin Retard L.U.T.,DHE 45,DHE Puren,DHE Ratiopharm,DHE45,Dihydroergotamine Sandoz,Mesylate, Dihydroergotamine,Methanesulfonate, Dihydroergotamine,Von Ct, Ergotam
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic

Related Publications

K Wilsmann, and G Neugebauer, and R Kessel, and E Lang
August 1981, Fortschritte der Medizin,
K Wilsmann, and G Neugebauer, and R Kessel, and E Lang
July 1986, Lancet (London, England),
K Wilsmann, and G Neugebauer, and R Kessel, and E Lang
April 2012, The Journal of physiology,
K Wilsmann, and G Neugebauer, and R Kessel, and E Lang
November 1988, Canadian journal of physiology and pharmacology,
K Wilsmann, and G Neugebauer, and R Kessel, and E Lang
January 1981, Pharmacology,
K Wilsmann, and G Neugebauer, and R Kessel, and E Lang
January 1988, Methods and findings in experimental and clinical pharmacology,
K Wilsmann, and G Neugebauer, and R Kessel, and E Lang
November 2000, European journal of applied physiology,
K Wilsmann, and G Neugebauer, and R Kessel, and E Lang
October 1981, Clinical physiology (Oxford, England),
Copied contents to your clipboard!